DE50214008D1 - Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein - Google Patents

Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein

Info

Publication number
DE50214008D1
DE50214008D1 DE50214008T DE50214008T DE50214008D1 DE 50214008 D1 DE50214008 D1 DE 50214008D1 DE 50214008 T DE50214008 T DE 50214008T DE 50214008 T DE50214008 T DE 50214008T DE 50214008 D1 DE50214008 D1 DE 50214008D1
Authority
DE
Germany
Prior art keywords
metastases
binding molecule
tumors
medicament
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE50214008T
Other languages
German (de)
English (en)
Inventor
Franz Paul Armbruster
Markus Karmatschek
Werner Franz Nader
Ulf Joerg Forsmann
Mats Paulsson
Martin R Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Armbruster Biotechnology GmbH
Original Assignee
Armbruster Biotechnology GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armbruster Biotechnology GmbH filed Critical Armbruster Biotechnology GmbH
Application granted granted Critical
Publication of DE50214008D1 publication Critical patent/DE50214008D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE50214008T 2001-06-13 2002-06-12 Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein Expired - Lifetime DE50214008D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01114388 2001-06-13
DE10128639 2001-06-15
PCT/EP2002/006456 WO2002100899A2 (de) 2001-06-13 2002-06-12 Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein

Publications (1)

Publication Number Publication Date
DE50214008D1 true DE50214008D1 (de) 2009-12-31

Family

ID=26009516

Family Applications (1)

Application Number Title Priority Date Filing Date
DE50214008T Expired - Lifetime DE50214008D1 (de) 2001-06-13 2002-06-12 Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein

Country Status (10)

Country Link
US (2) US7825219B2 (enExample)
EP (1) EP1399186B1 (enExample)
JP (1) JP4570355B2 (enExample)
AT (1) ATE448796T1 (enExample)
AU (1) AU2002319223A1 (enExample)
DE (1) DE50214008D1 (enExample)
DK (1) DK1399186T3 (enExample)
ES (1) ES2336770T3 (enExample)
PT (1) PT1399186E (enExample)
WO (1) WO2002100899A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1514929A1 (en) * 2003-09-12 2005-03-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense oligonucleotides for prevention of metastasis formation of cancer cells
ATE443718T1 (de) 2005-05-31 2009-10-15 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
EP1931994A2 (en) * 2005-09-26 2008-06-18 Novartis AG Molecular markers associated with bone metastasis
MX2011001930A (es) * 2008-08-29 2011-04-21 Symphogen As Metodo para clonar anticuerpos derivados de aves.
CA2958263C (en) 2014-08-19 2022-12-13 Immundiagnostik Ag Medicament and apparatus for treating chronic kidney disease
CA3226401A1 (en) * 2021-07-20 2023-01-26 William Marsh Rice University Engineered compositions for bone-targeted therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853219A (en) * 1987-08-06 1989-08-01 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5340934A (en) * 1989-11-03 1994-08-23 The United States Of Americas As Represented By The Secretary Of Health & Human Services CDNA sequences of human bone matrix proteins
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP1169642B1 (en) * 1999-04-09 2006-01-04 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Complex formed by n-linked glycoproteins (siblings) and factor h

Also Published As

Publication number Publication date
EP1399186A2 (de) 2004-03-24
DK1399186T3 (da) 2010-03-29
WO2002100899A3 (de) 2003-12-18
ATE448796T1 (de) 2009-12-15
US20110091379A1 (en) 2011-04-21
ES2336770T3 (es) 2010-04-16
PT1399186E (pt) 2010-02-23
US7825219B2 (en) 2010-11-02
WO2002100899A2 (de) 2002-12-19
US20050069547A1 (en) 2005-03-31
JP2005506959A (ja) 2005-03-10
US8808691B2 (en) 2014-08-19
JP4570355B2 (ja) 2010-10-27
AU2002319223A1 (en) 2002-12-23
EP1399186B1 (de) 2009-11-18

Similar Documents

Publication Publication Date Title
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
EP2322215A3 (en) Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
SE0102147D0 (sv) New methods
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
DK1643999T3 (da) Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
SE9902597D0 (sv) New use
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
ATE265225T1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition